United Kingdom CBD trade group calls for long-awaited regulations
The Association of the Cannabinoid Industry trade group in the United Kingdom says the country’s Home Office is taking too long to implement a legal framework for CBD.
The Association of the Cannabinoid Industry trade group in the United Kingdom says the country’s Home Office is taking too long to implement a legal framework for CBD.
Canadian licensed producer Organigram Holdings has struck a supply agreement with 4C Labs to provide dried medical cannabis flower for the United Kingdom market.
British CBD maker Love Hemp Group was fined 100,000 pounds ($118,347) by the London-based Aquis Stock Exchange for misleading investors by announcing a capital raise of 2 million pounds that was not completed.
Trip, a CBD company based in the United Kingdom, said it raised $12 million in fresh capital from entrepreneurs, business leaders and other investors.
British food regulators hit the pause button on plans to winnow edible CBD products that can be sold in the United Kingdom.
Medical marijuana will be available by prescription in the United Kingdom by autumn after it was formally approved by the government Thursday.
After the UK’s medical cannabis market opens in the fall, it will immediately become one of the largest in Europe.
Curaleaf Holdings is continuing its international expansion by signing a deal to acquire Northern Green Canada, a licensed cannabis producer focused primarily on meeting demand in the import-export market.
Medical cannabis companies from Canada and Britain are joining forces to create a global, vertically integrated business to tap opportunities in Europe and beyond.
Germany’s chief legislative body on Friday approved a landmark recreational cannabis bill that’s being simultaneously hailed as a generational milestone and “quasi legalization” because the new law stops short of implementing a framework for the distribution and retail sale of adult-use products.
Canadian cannabis producer Canopy Growth on Friday reported a shake-up to its board of directors, a lower third-quarter loss and a “singular focus” on marijuana.